Medicare Enrolled

Dr. Anthony Botti, M.D.

Hematology & Oncology · Livingston, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
349 E NORTHFIELD RD, Livingston, NJ 07039
9735970900
In practice since 2006 (19 years)
NPI: 1598787640 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Botti from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Botti? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Botti

Dr. Anthony Botti is a hematology & oncology specialist in Livingston, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Botti performed 166,169 Medicare services across 2,433 unique beneficiaries.

Between the years covered by Open Payments, Dr. Botti received a total of $422,987 from 49 pharmaceutical and/or device companies across 911 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Botti is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 3% volume in NJ $422,987 industry payments

Medicare Practice Summary

Medicare Utilization ↗
166,169
Medicare services
Top 3% in NJ for hematology & oncology
2,433
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,746 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 86,400 $18 $27
Iron infusion (Injectafer)
An intravenous injection of ferric carboxymaltose, an iron replacement medication.
36,750 $1 $2
Vedolizumab infusion (Entyvio)
This procedure involves the administration of vedolizumab via injection. The dosage is measured in milligrams.
25,800 $17 $25
Romosozumab injection (Evenity) for osteoporosis 13,860 $8 $11
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
1,292 $67 $102
Zoledronic acid injection, 1 mg
An injection of zoledronic acid administered at a dose of 1 mg.
990 $6 $80
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
340 $121 $250
Intravenous infusion, 1 hour or less
Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less.
312 $56 $175
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
309 $12 $52
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
116 $26 $120
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
38.0% high complexity
62.0% medium
0.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$422,987
Total received (2018-2024)
Avg $60,427/year across 7 years
Top 2% in NJ for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
49
Companies
911
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$410,203 (97.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,839 (1.6%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$5,945 (1.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$800
2023
$6,676
2022
$52,206
2021
$32,790
2020
$51,481
2019
$130,003
2018
$149,032

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$168
Lilly USA, LLC
$166
Eisai Inc.
$121
Lundbeck LLC
$80
Gilead Sciences, Inc.
$79
Alexion Pharmaceuticals, Inc.
$66
Novartis Pharmaceuticals Corporation
$66
Takeda Pharmaceuticals U.S.A., Inc.
$36
Janssen Biotech, Inc.
$18
Top 3 companies account for 56.9% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$202,936
Incyte Corporation
$119,698
Dova Pharmaceuticals
$52,501
Sobi, Inc
$26,581
NOVARTIS PHARMACEUTICALS CORPORATION
$8,235
Alexion Pharmaceuticals, Inc.
$3,419
Apellis Pharmaceuticals, Inc.
$3,382
Amgen Inc.
$1,263
Daiichi Sankyo Inc.
$652
Pharmacyclics LLC, An AbbVie Company
$507
Horizon Therapeutics plc
$456
Takeda Pharmaceuticals U.S.A., Inc.
$445
Genentech USA, Inc.
$398
Gilead Sciences, Inc.
$336
Janssen Biotech, Inc.
$294
Lundbeck LLC
$207
Lilly USA, LLC
$166
AstraZeneca Pharmaceuticals LP
$134
Eisai Inc.
$121
Celgene Corporation
$84
GlaxoSmithKline, LLC.
$84
Otsuka America Pharmaceutical, Inc.
$84
AMAG Pharmaceuticals, Inc.
$84
EUSA Pharma (US) LLC
$76
Octapharma USA, Inc.
$75
PFIZER INC.
$70
Merck Sharp & Dohme LLC
$69
Bayer HealthCare Pharmaceuticals Inc.
$67
E.R. Squibb & Sons, L.L.C.
$53
Biogen, Inc.
$47
Global Blood Therapeutics, Inc.
$42
GENZYME CORPORATION
$40
Shire North American Group Inc
$40
Rigel Pharmaceuticals, Inc.
$30
Endo Pharmaceuticals Inc.
$29
ABBVIE INC.
$28
Astellas Pharma US Inc
$27
Sandoz Inc.
$26
Pharmacosmos Therapeutics Inc.
$25
Merck Sharp & Dohme Corporation
$25
Seqirus USA Inc
$24
Janssen Pharmaceuticals, Inc
$24
Novo Nordisk Inc
$17
Boehringer Ingelheim Pharmaceuticals, Inc.
$17
Horizon Pharma plc
$15
AbbVie Inc.
$14
Teva Pharmaceuticals USA, Inc.
$13
Organon LLC
$12
Amarin Pharma Inc.
$12
Top 3 companies account for 88.7% of all-time payments
Associated products mentioned in payments ›
ADAKVEO · ADUHELM · Actemra · Aliqopa · BENLYSTA · BOSULIF · CALQUENCE · CEREZYME · CINQAIR · COSENTYX · CRIZANLIZUMAB · DIFICID · DOPTELET · Doptelet · EMPAVELI · ENTYVIO · EVENITY · Empaveli · Entyvio · Erleada · FERAHEME · Fluad · IMBRUVICA · INFLECTRA · INJECTAFER · INREBIC · Imbruvica · Inrebic · JADENU · JAKAFI · KISQALI · KRYSTEXXA · LEMTRADA · LEQVIO · Leqembi · MONJUVI · MORPHABOND · Monoferric · NASCOBAL · NINLARO · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OMVOH · ONCASPAR · ONTRUZANT · OPDIVO · OXBRYTA · Ocrevus · PIFELTRO · PROMACTA · Prolia · REBLOZYL · RYDAPT · Reblozyl · Rituxan · SAMSCA · SAPHNELO · SCEMBLIX · SIMPONI ARIA · SKYRIZI · SOLIRIS · SPEVIGO · SPRYCEL · STELARA · Saxenda · Soliris · Strensiq · Sylvant · TASIGNA · TREMFYA · TYSABRI · Tavalisse · ULTOMIRIS · UPLIZNA · Ultomiris · VPRIV · VYEPTI · Vascepa · WILATE · WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN) · Welchol · XARELTO · XOSPATA · Xofigo
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (97%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 2% for hematology & oncology in NJ.

Looking for a hematology & oncology specialist in Livingston?
Compare hematology & oncology specialists in the Livingston area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
615
Per 100K population
72.0
County median income
$76,712
Nearest hospital
COOPERMAN BARNABAS MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Botti is a mixed practice specialist, with above-average Medicare volume (top 3% in NJ), with speaking/promotional industry engagement in the top 2% of NJ peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Botti experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Botti performed 86,400 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Botti receive payments from pharmaceutical companies?
Yes. Dr. Botti received a total of $422,987 from 49 companies across 911 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Botti's costs compare to other hematology & oncology specialists in Livingston?
Dr. Botti's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Botti) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →